An Overview of Daiichi Sankyo’s Drug Pipeline

Daiichi Sankyo Co., Ltd. is a pharmaceutical organization based in Tokyo-to, Japan. It was founded in 2005 and has since become a prominent player in the biomedicine industry. The company has a diverse portfolio of drugs that target various therapeutic areas, with a particular focus on neoplasms, nervous system diseases, and skin and musculoskeletal diseases. Shanghai Daiichi Sankyo Pharmaceutical Co., Ltd. (formerly known as Shanghai Sankyo Pharmaceutical Co., Ltd.) was established in Shanghai Zhangjiang Hi-Tech Park in 1999 and is a wholly-owned subsidiary of Daiichi Sankyo Co., Ltd. Mainly engaged in the development, production, sales and consulting of pharmaceutical products, as well as the import, export and wholesale of pharmaceutical products.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of Daiichi Sankyo.

Daiichi Sankyo Co., Ltd. has developed a significant number of drugs in the field of neoplasms, with a count of 53. This indicates the company's commitment to addressing the challenges posed by cancer and developing innovative treatments. Nervous system diseases and skin and musculoskeletal diseases are also areas of focus for the organization, with drug counts of 47 each. This suggests that Daiichi Sankyo Co., Ltd. recognizes the importance of addressing conditions related to the central and peripheral nervous systems, as well as disorders affecting the skin and musculoskeletal system.

Cardiovascular diseases and respiratory diseases are also areas in which Daiichi Sankyo Co., Ltd. has a significant presence, with drug counts of 39 each. This highlights the company's dedication to developing treatments for conditions such as heart disease, hypertension, and respiratory disorders. Endocrinology and metabolic diseases, infectious diseases, and other diseases are also therapeutic areas in which the organization has made substantial contributions, with drug counts of 37, 33, and 29 respectively. Daiichi Sankyo Co., Ltd. has developed drugs targeting immune system diseases, digestive system disorders, urogenital diseases, hemic and lymphatic diseases, congenital disorders, mouth and tooth diseases, otorhinolaryngologic diseases, and eye diseases. While the drug counts for these areas are relatively lower, it demonstrates the company's commitment to addressing a wide range of medical conditions.

Specific molecular targets developed by Daiichi Sankyo

It is evident that Daiichi Sankyo Co., Ltd. has focused on developing drugs targeting specific molecular targets. Dystrophin, ACE, and PBPs are the most frequently developed targets, with drug counts of 5, 3, and 3 respectively. This suggests that the organization recognizes the importance of targeting specific molecules involved in disease processes to develop effective treatments. Other targets that have been the focus of drug development include BRD4, sodium channels, bacterial Top II, MLL1 + menin, KLK5, CD276, and Phospho-N-acetylmuramoyl pentapeptide transferase.

The pipeline of Daiichi Sankyo 

The organization has drugs in various stages of development, starting from the discovery phase to the approved phase. As of the given date, there are 3 drugs in the discovery phase, 28 drugs in the preclinical phase, 21 drugs in phase 1, 22 drugs in phase 2, and 6 drugs in phase 3. Additionally, there is 1 drug in the NDA/BLA (New Drug Application/Biologics License Application) stage and 87 drugs that have been approved. The pipeline also includes 228 drugs categorized as "Other," which could refer to drugs in various stages of development or those that do not fit into the specified categories.

In summary, Daiichi Sankyo Co., Ltd. is a pharmaceutical organization based in Tokyo-to, Japan, with a strong presence in the biomedicine industry. The company has developed a diverse portfolio of drugs targeting various therapeutic areas, including neoplasms, nervous system diseases, and skin and musculoskeletal diseases. Daiichi Sankyo Co., Ltd. has also focused on developing drugs targeting specific molecular targets, such as dystrophin, ACE, and PBPs. The organization has an extensive pipeline of drugs in various stages of development, indicating its commitment to innovation and addressing unmet medical needs.